ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has completed the placement of 33,150,000 shares to at least six investors at HK$7.05 apiece to raise net proceeds of HK$229.7 million, a Thursday bourse filing said.
The shares represent around 8.14% of the pharmaceutical company's enlarged issued share capital.
The company will use proceeds from the placement to fund clinical studies of different drugs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。